Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11108209 | 0.83 | GAA (0.56) | GAAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL9228069 | 0.83 | GAA (0.46) | GAAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL12831543 | 0.82 | F10 (0.47) | GAARAB9ACA12CA1CA2 | |
| SCHEMBL11407076 | 0.81 | GAA (0.58) | GAAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4791618 | 0.81 | GAA (0.58) | GAAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL11821170 | 0.81 | GAA (0.58) | GAAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL2866545 | 0.81 | GAA (0.58) | GAAADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL9627103 | 0.80 | SLC2A1 (0.46) | GAAADRA2AADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL6232272 | 0.79 | GAA (0.56) | GAAADRA2AADRA2CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL31451442 | 0.79 | GAA (0.56) | GAAADRA2AADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384080-A | Synthesis method of N-methyl-2-phenylindole | 南京工业大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-16 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| WO-2023102140-A1 | TMPRSS2 INHIBITORS AND METHODS OF USE | TOPSPIN THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11339180-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2022-05-24 | — | — | US | disclosed |
| US-11186566-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210246146-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2021-08-12 | — | — | US | disclosed |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| US-4952731-A | Process for producing diphenylamines or N,N'-diphenyl-phenylenediamines | MITSUI TOATSU CHEMICALS, INC. (JP) | 1990-08-28 | — | — | US | disclosed |
| US-4871875-A | Process for producing diphenylamines or N,N'-diphenylphenylenediamines | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-10-03 | — | — | US | disclosed |
| US-4804783-A | Process for producing diphenylamines or N,N'-diphenyl-phenylenediamines | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186566-B2 | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, ABCB11 | GAA 1433/4885ADRA2A 345/4885ADRA2C 418/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | GAA 4127/4885ADRA2A 280/4885ADRA2C 658/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | GAA 2452/4885ADRA2A 1095/4885ADRA2C 1565/4885 |
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, TYMP, TPMT | GAA 2163/4885ADRA2A 3160/4885ADRA2C 1952/4885 |
| US-20230365559-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | DCK, DTYMK, TYMP | GAA 2100/4885ADRA2A 1397/4885ADRA2C 852/4885 |
| US-11339180-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | GAA 49/4885ADRA2A 4412/4885ADRA2C 4243/4885 |
| US-20210246146-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | GAA 49/4885ADRA2A 4412/4885ADRA2C 4243/4885 |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | GAA 3776/4885ADRA2A 2686/4885ADRA2C 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.